Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study - Armoiry, X.; Fagnani, F.; Benboubker, L.; Facon, T.; Fermand, J. P.; Hulin, C.; Moreau, P.; Aulagner, G. (Journal of clinical pharmacy and therapeutics, 2011)
Keywords: Aged; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - economics; Antineoplastic Agents - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - economics; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Boronic Acids - administration & dosage; Boronic Acids - economics; Boronic Acids - therapeutic use; Bortezomib; cohort; Cohort Studies; Drug Costs - statistics & numerical data; Drug Resistance, Neoplasm; Drug Utilization - statistics & numerical data; Female; France; Health Care Costs - statistics & numerical data; Hematologic and hematopoietic diseases; Hospitals, University; Humans; Immunodeficiencies. Immunoglobulinopathies; Immunoglobulinopathies; Immunopathology; lenalidomide; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Male; Medical Records; Medical sciences; Middle Aged; Multiple Myeloma - drug therapy; Multiple Myeloma - economics; novel agents; Pharmacology. Drug treatments; Practice Patterns, Physicians' - statistics & numerical data; Pyrazines - administration & dosage; Pyrazines - economics; Pyrazines - therapeutic use; Recurrence; relapse or refractory multiple myeloma; retrospective analysis; Retrospective Studies; thalidomide; Thalidomide - administration & dosage; Thalidomide - analogs & derivatives; Thalidomide - economics; Thalidomide - therapeutic use; France; Europe; Antineoplastic agent; Relapse; Psychotropic; cohort; Myeloma; novel agents; Immunoglobulinopathy; Lymphoproliferative syndrome; Cohort study; Hospital; Sedative; Antiangiogenic agent; Thalidomide; Public health; Human; Immunopathology; Treatment resistance; Antileprous agent; Bortezomib; Lenalidomide; Hypnotic; Malignant hemopathy; Anti-Tumor Necrosis Factor-alpha; Retrospective; relapse or refractory multiple myeloma; Immunomodulator; retrospective analysis; Clinical management; Follow up study; Analog; Proteasome inhibitor; Dipeptides; Antibacterial agent; Cancer